Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 5Phase 1/2 4Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 7Somatostatinoma 2Gastroenteropancreatic Neuroendocrine Tumors 2Adenoma, Islet Cell 2Vipoma 1Pheochromocytoma 1Paraganglioma 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1Carcinoid Tumor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Pheochromocytoma × NET × Clear all
NCT00442533 2023-04-03

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Radio Isotope Therapy of America

Phase 2/3 Completed
200 enrolled
CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Somatostatinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡